The Filing Desk

Liquidia vs Stoke Therapeutics

Liquidia LQDA · Stoke Therapeutics STOK · Pharmaceuticals

Stoke Therapeutics reported revenue of $184 million in fiscal 2025, 1.2 times Liquidia's $158 million in fiscal 2025. Liquidia's revenue grew 1031.2% in its latest year, and Stoke Therapeutics' grew 404.5%. Liquidia had an operating margin of -32.5%, against -11.2% at Stoke Therapeutics. Free cash flow was −$40 million at Liquidia and $45 million at Stoke Therapeutics.

Side by side

LiquidiaStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$158M$184M
Revenue growth1,031.2%404.5%
Revenue growth a year, last 5 years195.7%—
Gross margin——
Operating margin−32.5%−11.2%
Net margin−43.5%−3.7%
Free cash flow−$40M$45M
Free cash flow margin−25.3%24.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count9.3%9.7%
Last close$57.41$26.68
P/E at the last close——
Insider trades, last 12 monthsbought $317,894, sold $218.7 millionsold $8.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
LiquidiaStoke Therapeutics
Operating margin
Percent of revenue
LiquidiaStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LiquidiaStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Liquidia and Stoke Therapeutics pages.